Connect with us
Novo Nordisk's experimental weight-loss pill, amycretin, showed promising early-phase results, with patients losing up to 13.1% of their weight in 12 weeks. Side effects were mild...
Denmark's GDP is expected to grow by 1.8% in 2024, revised down from 2.1%, with 2% growth anticipated in 2025. Denmark outpaces Nordic peers, with Sweden...
In the first half of the year, Novo Nordisk saw significant growth in sales, with Ozempic revenue up 36% to 56.685 billion crowns (€7.596 billion) and...
Until now, in the field of anti-obesity treatments, there was a drug that attracted attention: Ozempic. It is also made by Novo Nordisk and is very...
Novo Nordisk sees substantial growth, reporting a 28% increase in profits to €3.4 billion in Q1 2024, with operating profits up 27% to €4.27 billion. This...
Wegovy stands as Novo Nordisk's big bet. This medicine was what placed the Danish multinational company as the most valuable company in Europe last September, surpassing...